Zobrazeno 1 - 10
of 202
pro vyhledávání: '"Aaron E Miller"'
Autor:
James F. Sumowski, Sam Horng, Rachel Brandstadter, Stephen Krieger, Victoria M. Leavitt, Ilana Katz Sand, Michelle Fabian, Sylvia Klineova, Robin Graney, Claire S. Riley, Fred D. Lublin, Aaron E. Miller, Andrew W. Varga
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 8, Iss 6, Pp 1172-1182 (2021)
Abstract Objective Sleep‐dependent memory processing occurs in animals including humans, and disturbed sleep negatively affects memory. Sleep disturbance and memory dysfunction are common in multiple sclerosis (MS), but little is known about the co
Externí odkaz:
https://doaj.org/article/4678af593570441c83430984cd6a690d
Autor:
Aaron E. Miller, Tracy M. DeAngelis
What Do I Do Now? Patients with neuroimmunological syndromes pose many clinical challenges for the attending physician. Even experienced clinicians occasionally arrive at the point where diagnostic, work-up, treatment, or prognostic thinking becomes
Publikováno v:
Neurotoxicity Research. 40:1464-1478
Autor:
Till Sprenger, Ludwig Kappos, Maria Pia Sormani, Aaron E Miller, Elizabeth M Poole, Steven Cavalier, Jens Wuerfel
Publikováno v:
Multiple Sclerosis Journal. 28:1719-1728
Background: In post hoc analyses of Teriflunomide Multiple Sclerosis Oral study (TEMSO; NCT00134563), teriflunomide 14 mg significantly reduced brain volume loss (BVL) versus placebo in patients with relapsing multiple sclerosis (MS). Objective: In t
Autor:
Aaron E. Miller
Publikováno v:
Neurodegenerative Disease Management. 11:387-409
Teriflunomide, a once daily, oral disease-modifying therapy, has demonstrated consistent efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis (MS) and with a first clinical episode suggestive of MS treated up to 12
Autor:
Aaron E. Miller
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 10 (2017)
Key objectives in the treatment of multiple sclerosis (MS) include prevention of relapses, a reduction in the accumulation of disability and slowing of the brain volume loss that occurs from the earliest stages of the disease. Teriflunomide, a once-d
Externí odkaz:
https://doaj.org/article/3549b8dfa44d47a495efd39e860db6c8
Autor:
Sylvia Klineova, James F. Sumowski, Claire S Riley, Daniel Kurz, Fred D. Lublin, Rachel Brandstadter, Aaron E. Miller, Michelle Fabian, Lisa Glukhovsky, Ilana Katz Sand, Stephen Krieger, Victoria M. Leavitt
Publikováno v:
Multiple Sclerosis Journal. 27:1276-1283
Background: Persons with multiple sclerosis (MS) and depression symptoms report real-world cognitive difficulties that may be missed by laboratory cognitive tests. Objective: To examine the relationship of depressive symptoms to cognitive monotasking
Autor:
Noam Y. Harel, Oluwasheyi Ayeni, Korhan Buyukturkoglu, Ilana Katz Sand, Aaron E. Miller, Stephen Krieger, Michelle Fabian, Rachel Brandstadter, Sylvia Klineova, Victoria M. Leavitt, James F. Sumowski, Miguel X. Escalon, Fred D. Lublin, Claire S Riley
Publikováno v:
Neurology
ObjectiveTo test the hypothesis that higher-challenge gait and balance tasks are more sensitive than traditional metrics to subtle patient-reported gait dysfunction and future fall risk in early multiple sclerosis (MS).MethodsPersons with early MS (n
Autor:
Reed Johnson, Anne Rollins, Robert Elfont, Andrew D. Goodman, Jeffrey A. Cohen, Rajiv Patni, Lily Llorens, Aaron E. Miller, Myla D. Goldman, Michelle Cameron
Publikováno v:
Multiple sclerosis (Houndmills, Basingstoke, England). 28(5)
Background: ADS-5102, a delayed-release, extended-release (DR/ER) amantadine, improved walking speed in MS in a Phase 2 trial. Objective: The aim of this study was to present primary results of a Phase 3, double-blind, ADS-5102 trial (INROADS) for wa
Autor:
Myriam Benamor, Jiwon Oh, Aaron E. Miller, Jerry S. Wolinsky, Annie Purvis, Jérôme De Seze, Ludwig Kappos, Patrick Vermersch, Mark S. Freedman, Philippe Truffinet, Giancarlo Comi
Publikováno v:
Multiple Sclerosis and Related Disorders. 33:131-138
Background In the phase 3 TOPIC study, teriflunomide significantly reduced the risk of relapse determining conversion to clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndrome, versus placebo. We assessed clinical